AAV7

AAV7
Name	Adeno-associated virus serotype 7
Virus group	Parvoviridae
Genus	Dependoparvovirus
Species	Adeno-associated virus
Genome	Single-stranded DNA
Capsid	Non-enveloped, icosahedral
Diameter	~25 nm

AAV7 Adeno-associated virus serotype 7 is a member of the Parvoviridae family and the Dependoparvovirus genus, used extensively as a vector in experimental gene therapy and molecular biology research. First characterized in the context of serological surveys alongside serotypes such as AAV2 and AAV5, it has been evaluated in preclinical models spanning neurology, ophthalmology, and metabolic disease studies. Comparative studies often reference serotypes like AAV1, AAV8, and AAV9 when assessing transduction efficiency, tissue tropism, and immunogenic profiles.

Introduction

AAV7 was identified through serotyping efforts that included contributions from institutions such as the National Institutes of Health and collaborations involving investigators affiliated with Harvard Medical School and University of Pennsylvania. In vectorology literature, AAV7 is discussed alongside historic milestones like the discovery of adeno-associated virus biology by researchers connected to Cold Spring Harbor Laboratory and clinical milestones that include trials conducted at centers such as Mayo Clinic and Stanford University School of Medicine. It occupies a role in translational pipelines influenced by regulatory precedents set by agencies such as the U.S. Food and Drug Administration and the European Medicines Agency.

Virology and Genome

AAV7 possesses a ~4.7 kilobase single-stranded DNA genome flanked by inverted terminal repeats similar to other serotypes characterized in foundational studies at Cold Spring Harbor Laboratory and Massachusetts Institute of Technology. The genome encodes the Rep and Cap gene clusters—Rep proteins and capsid VP1/VP2/VP3—that determine replication and packaging, topics examined in mechanistic work from laboratories at Johns Hopkins University and University of California, San Francisco. Packaging capacity and genome design for AAV7 vectors often reference strategies developed in seminal methods papers originating from groups at University of Pennsylvania and University College London.

Tropism and Receptor Usage

AAV7 displays distinct tissue tropism that has been mapped in comparative studies with serotypes like AAV1, AAV6, and AAV9, reporting efficient transduction in tissues such as skeletal muscle and liver in models from research centers including University of Oxford and Columbia University. Receptor usage studies implicate cell-surface glycans and coreceptors identified in biochemical analyses conducted at institutions like Scripps Research and Max Planck Institute, with uptake pathways compared to those elucidated for serotypes examined by teams at Yale University and University of Pennsylvania. Tropism data inform targeting strategies in translational projects affiliated with clinical sites such as Cleveland Clinic and Great Ormond Street Hospital.

Production and Purification

Manufacturing of AAV7 vectors uses transient transfection or helper virus-free systems developed in process labs at GMP facilities and academic centers such as MIT and UC Berkeley. Upstream processes often adapt plasmid systems and triple-transfection protocols popularized by groups at University of North Carolina at Chapel Hill and University of Texas Southwestern Medical Center, while downstream purification leverages chromatography approaches refined by industry partners including Pfizer and Novartis. Scale-up considerations parallel experiences from commercial AAV programs at companies like Spark Therapeutics and uniQure.

Clinical and Research Applications

AAV7 has been employed in preclinical programs targeting inherited disorders and acquired diseases, with experimental applications informed by translational frameworks at Children's Hospital of Philadelphia and Baylor College of Medicine. Research use includes neuromodulation studies citing comparisons to vectors used in landmark trials at Massachusetts General Hospital and ocular gene delivery investigations referencing protocols developed at Bascom Palmer Eye Institute and Moorfields Eye Hospital. Investigators drawing on gene-editing platforms from groups at Broad Institute and CRISPR Therapeutics have packaged nucleases and expression cassettes into AAV7-based constructs for proof-of-concept work.

Safety and Immunogenicity

Immunogenicity assessments for AAV7 reference neutralizing antibody surveys analogous to those reported for serotypes in population studies coordinated by Centers for Disease Control and Prevention and academic consortia from Stanford University and University of California, Los Angeles. Preclinical toxicity and biodistribution studies follow guidance shaped by precedent trials conducted at NIH Clinical Center and safety frameworks from European Medicines Agency, evaluating innate and adaptive responses characterized by immunologists at La Jolla Institute and Institut Pasteur. Strategies to mitigate immune recognition draw on approaches developed by teams at Genentech and Regeneron Pharmaceuticals.

Regulatory and Manufacturing Considerations

Advancement of AAV7 into clinical pipelines navigates regulatory pathways established through landmark approvals and guidance documents issued by U.S. Food and Drug Administration and European Medicines Agency, with manufacturing standards aligned to Good Manufacturing Practice principles practiced at contract manufacturing organizations like CROs and biotech sites such as Lonza and Sartorius. Intellectual property and licensing considerations reflect precedent cases involving universities including Columbia University and companies such as UniQure and Spark Therapeutics, while consortium efforts led by institutions like Battelle and Innovation Medicines address supply-chain and scale challenges.

Category:Dependoparvovirus